Concepedia

Safety, Efficacy, and Patient-Reported Health-Related Quality of Life and Symptom Burden with Nivolumab in Patients with Advanced Non–Small Cell Lung Cancer, Including Patients Aged 70 Years or Older or with Poor Performance Status (CheckMate 153)

David R. Spigel, Michael McCleod, Robert M. Jotte, Lawrence H. Einhorn, Leora Horn, David Waterhouse, Ben Creelan, Sunil Babu, Natasha B. Leighl, Jason C. Chandler,

Journal of Thoracic Oncology · 2019 · 187 citations · 12 references

References

12

Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

H. Borghaei, L. Paz-Ares, Leora Horn et al. · New England Journal of Medicine · 2015 · 9.5K citations · Full text

Life Sciences, Oncology, Pharmacotherapy +17

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer

Julie R. Brahmer, Karen L. Reckamp, Lucio Crinò et al. · New England Journal of Medicine · 2015 · 8.6K citations · Full text

Pharmacy, Oncology, Pharmacotherapy +15

Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer

A. Simon Pickard, Maureen P. Neary, David Cella · Health and Quality of Life Outcomes · 2007 · 924 citations · Full text

Pharmacy, Oncology, Health Assessment +16

Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057)

Leora Horn, David R. Spigel, Everett E. Vokes et al. · Journal of Clinical Oncology · 2017 · 875 citations · Full text

Medicine, Oncology, Pharmacology +16

Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases

E.E. Vokes, Neal Ready, Enriqueta Felip et al. · Annals of Oncology · 2018 · 469 citations · Full text

Medicine, Oncology, Pharmacology +17